New trials and tribulations in drugging KRAS mutations
Is the ride going to be a thrilling long or disappointingly short one?
The KRAS niche continues to rattle on at an incredible pace with new findings, new trials, or even a new molecular entity (NME) coming along seemingly every month.
In this latest update on the landscape, we discuss some important new findings, as well as a novel agent to thing about in this space, which is quite different from what we have seen before.
To be clear – this doesn’t mean a novel approach doesn’t have any legs, nor that the latest science behind where we should be going with combinations is doomed. Indeed, sometimes finding a balance is a bit akin to a highwire act.
The important thing is to focus on the learnings and determine where the field might be headed…
BSB subscribers can read up on our ongoing commentary and analysis from the cancer conference season – you can either log-in or click to access our latest analysis.
This content is restricted to subscribers
